JPH0667830B2 - カルビドパ／レボドパの制御放出配合剤 - Google Patents
カルビドパ／レボドパの制御放出配合剤Info
- Publication number
- JPH0667830B2 JPH0667830B2 JP63309001A JP30900188A JPH0667830B2 JP H0667830 B2 JPH0667830 B2 JP H0667830B2 JP 63309001 A JP63309001 A JP 63309001A JP 30900188 A JP30900188 A JP 30900188A JP H0667830 B2 JPH0667830 B2 JP H0667830B2
- Authority
- JP
- Japan
- Prior art keywords
- levodopa
- carbidopa
- soluble polymer
- polymer
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 title claims abstract description 11
- 238000013270 controlled release Methods 0.000 title claims abstract description 11
- 229940052036 carbidopa / levodopa Drugs 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 229920000642 polymer Polymers 0.000 claims abstract description 25
- 238000009472 formulation Methods 0.000 claims abstract description 23
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 32
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 31
- 229960004502 levodopa Drugs 0.000 claims description 29
- 229920003169 water-soluble polymer Polymers 0.000 claims description 11
- 229960004205 carbidopa Drugs 0.000 claims description 9
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 229920002554 vinyl polymer Polymers 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 2
- VSKCCZIUZNTICH-ZPYUXNTASA-N (e)-but-2-enoic acid;ethenyl acetate Chemical group C\C=C\C(O)=O.CC(=O)OC=C VSKCCZIUZNTICH-ZPYUXNTASA-N 0.000 claims 1
- 230000000648 anti-parkinson Effects 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000007970 homogeneous dispersion Substances 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 21
- 239000011159 matrix material Substances 0.000 abstract description 15
- 238000011282 treatment Methods 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 5
- 206010034010 Parkinsonism Diseases 0.000 abstract description 2
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000003628 erosive effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000016285 Movement disease Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000012661 Dyskinesia Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229940001089 sinemet Drugs 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229940085760 carbidopa 25 mg Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 229940080381 levodopa 100 mg Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 1
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940097987 carbidopa 10 mg Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940080394 levodopa 250 mg Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13160187A | 1987-12-11 | 1987-12-11 | |
| US131,601 | 1987-12-11 | ||
| US07/223,861 US4832957A (en) | 1987-12-11 | 1988-07-25 | Controlled release combination of carbidopa/levodopa |
| US223,861 | 1988-07-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02209A JPH02209A (ja) | 1990-01-05 |
| JPH0667830B2 true JPH0667830B2 (ja) | 1994-08-31 |
Family
ID=26829626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63309001A Expired - Lifetime JPH0667830B2 (ja) | 1987-12-11 | 1988-12-08 | カルビドパ／レボドパの制御放出配合剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4832957A (enExample) |
| EP (1) | EP0320051B1 (enExample) |
| JP (1) | JPH0667830B2 (enExample) |
| KR (1) | KR890009377A (enExample) |
| AT (1) | ATE81970T1 (enExample) |
| AU (1) | AU616449B2 (enExample) |
| CA (1) | CA1318602C (enExample) |
| DE (1) | DE3875705T2 (enExample) |
| DK (1) | DK170515B1 (enExample) |
| ES (1) | ES2052691T3 (enExample) |
| GR (1) | GR3006220T3 (enExample) |
| HK (1) | HK7997A (enExample) |
| IE (1) | IE61547B1 (enExample) |
| IL (1) | IL88563A0 (enExample) |
| PT (1) | PT89157B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008087882A1 (ja) | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | 胃内滞留型レボドパ徐放性製剤 |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| JP2653061B2 (ja) * | 1986-12-27 | 1997-09-10 | 武田薬品工業株式会社 | 新規ポリペプチドおよびその製造法 |
| US5601835A (en) * | 1987-04-29 | 1997-02-11 | Massachusetts Institute Of Technology | Polymeric device for controlled drug delivery to the CNS |
| DE3933000A1 (de) * | 1989-10-03 | 1991-04-11 | Int Pharma Agentur | Erosionsgesteuertes wirkstoff-freigabesystem und verfahren zu seiner herstellung |
| US5006344A (en) * | 1989-07-10 | 1991-04-09 | E. R. Squibb & Sons, Inc. | Fosinopril tablet formulations |
| CA2037178A1 (en) * | 1990-02-28 | 1991-08-29 | Albert Walter Brzeczko | Deprenyl/l-dopa/carbidopa pharmaceutical composition |
| DE4101873C2 (de) * | 1991-01-23 | 1993-12-09 | Isis Pharma Gmbh | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände |
| US5624960A (en) * | 1991-01-23 | 1997-04-29 | Isis Pharma Gmbh | Orally administrable drugs for the treatment of central dopamine deficiency conditions |
| HU209564B (en) * | 1991-01-30 | 1994-07-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing rapide tablets containing levodopa and carbidopa |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| DE4226753A1 (de) * | 1992-08-13 | 1994-02-17 | Basf Ag | Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen |
| SE9203594D0 (sv) * | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| FR2725624B1 (fr) * | 1994-10-14 | 1997-01-17 | Jouveinal Inst Rech | Procede de preparation de formes pharmaceutiques a liberation controlee |
| US7179486B1 (en) | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
| US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
| US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US20040121014A1 (en) * | 1999-03-22 | 2004-06-24 | Control Delivery Systems, Inc. | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| WO2001015665A1 (en) | 1999-09-02 | 2001-03-08 | Nostrum Pharmaceuticals, Inc. | Controlled release oral dosage suitable for oral administration |
| US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| BR0309113A (pt) * | 2002-04-11 | 2005-02-01 | Ranbaxy Lab Ltd | Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| CA2501345A1 (en) * | 2002-10-11 | 2004-04-22 | Depomed Development, Ltd. | Gastro-retentive levodopa delivery form |
| ITMI20030827A1 (it) * | 2003-04-18 | 2004-10-19 | Unihart Corp | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. |
| PL1628642T3 (pl) * | 2003-05-14 | 2007-01-31 | Aptalis Pharma Ltd | Kontrolowane uwalnianie lekarstwa z kompozycji odpornej in vivo na mechaniczny stres |
| DE10346981A1 (de) * | 2003-10-09 | 2005-05-04 | Constr Res & Tech Gmbh | Verfahren zur Herstellung einer homogenen, niedrig-viskosen und Langzeit-stabilen Polymer-Dispersion in Mineralölen |
| KR100894465B1 (ko) * | 2003-10-20 | 2009-04-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 레보도파의 지속적 효과를 위한 조성물 및 제형 |
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
| US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| KR100866720B1 (ko) * | 2004-12-27 | 2008-11-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항치매 약물의 안정화 방법 |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| AU2006261893A1 (en) * | 2005-06-23 | 2007-01-04 | Combinatorx, Incorporated | Improved dosage forms for movement disorder treatment |
| SI1907382T1 (sl) * | 2005-07-26 | 2015-10-30 | Bial-Portela & Ca S.A., | Nitrokateholni derivati kot inhibitorji COMT |
| US20070275060A1 (en) * | 2005-08-05 | 2007-11-29 | Osmotica Costa Rica Sociedad Anonima | Extended release solid pharmaceutical composition containing carbidopa and levodopa |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| KR100838053B1 (ko) * | 2005-10-25 | 2008-06-12 | 중앙대학교 산학협력단 | 시토크롬 피450 85 에이 2 및 이의 이용 |
| US20070178149A1 (en) * | 2005-11-07 | 2007-08-02 | Moshe Flashner-Barak | Levodopa compositions |
| WO2007055329A1 (ja) | 2005-11-11 | 2007-05-18 | Asahi Kasei Chemicals Corporation | 徐放性固形製剤 |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| KR100756977B1 (ko) * | 2006-09-28 | 2007-09-07 | 한국전자통신연구원 | 휴대 인터넷 망과 인터넷 프로토콜 멀티미디어 서브시스템연동망에서 단말의 핸드오버 방법 및 장치 |
| AU2007338631A1 (en) * | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| KR100892220B1 (ko) * | 2007-07-02 | 2009-04-07 | 순천대학교 산학협력단 | 근사기법을 이용한 태양광 발전의 mppt 제어시스템 |
| CN101910113A (zh) | 2007-12-28 | 2010-12-08 | 怡百克制药公司 | 左旋多巴控释制剂及其用途 |
| ES2740360T3 (es) * | 2008-08-15 | 2020-02-05 | Assertio Therapeutics Inc | Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC |
| WO2011079232A1 (en) * | 2009-12-23 | 2011-06-30 | Psivida Us, Inc. | Sustained release delivery devices |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| JP6472391B2 (ja) * | 2013-03-13 | 2019-02-20 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | パーキンソン病の治療方法 |
| ES2823000T3 (es) | 2013-10-07 | 2021-05-05 | Impax Laboratories Llc | Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| PT3116475T (pt) | 2014-03-13 | 2020-12-15 | Neuroderm Ltd | Composições de inibidores de dopa-descarboxilase |
| WO2018011181A1 (en) | 2016-07-11 | 2018-01-18 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
| US11464756B1 (en) | 2017-05-19 | 2022-10-11 | Jerry Darm | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| JP2024501235A (ja) | 2020-12-22 | 2024-01-11 | アムニール ファーマスーティカルズ エルエルシー | レボドパ投薬レジメン |
| CN115737584A (zh) * | 2022-11-25 | 2023-03-07 | 石家庄四药有限公司 | 一种卡左双多巴缓释片及其制备方法 |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US29892A (en) * | 1860-09-04 | Spring-bedstead | ||
| US3632739A (en) * | 1969-12-29 | 1972-01-04 | Sandoz Ag | Solid sustained release pharmaceutical preparation |
| US3769424A (en) | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
| FR2211213B1 (enExample) * | 1972-12-26 | 1976-04-23 | Montagne Noire Prod Chim | |
| US3995058A (en) * | 1973-12-12 | 1976-11-30 | Miles Laboratories, Inc. | Treatment of ethanol withdrawal symptoms with levodopa |
| DE2513940A1 (de) * | 1975-03-29 | 1976-10-14 | Merck Patent Gmbh | Pharmazeutische zubereitung |
| US4389415A (en) * | 1978-01-24 | 1983-06-21 | Merck & Co., Inc. | Method of treating hypertension |
| US4190672A (en) * | 1978-09-01 | 1980-02-26 | Stanley Fahn | Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4469695A (en) * | 1980-02-25 | 1984-09-04 | Ayerst, Mckenna & Harrison, Inc. | 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives |
| US4469694A (en) * | 1980-02-25 | 1984-09-04 | Ayerst, Mckenna & Harrison Inc. | 2-(1-Piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives |
| US4469693A (en) * | 1980-02-25 | 1984-09-04 | Ayerst, Mckenna & Harrison Inc. | 2-(4-Substituted alkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives |
| US4329356A (en) * | 1980-10-31 | 1982-05-11 | Eli Lilly And Company | Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane |
| US4421767A (en) * | 1981-06-01 | 1983-12-20 | Merrell Toraude Et Compagnie | Compounds and methods for treating depression |
| US4413012A (en) * | 1981-06-01 | 1983-11-01 | Merrell Toraude Et Compagnie | Method for treating depression |
| EP0082880B1 (en) * | 1981-07-08 | 1986-06-11 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
| US4424235A (en) * | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| JPS5852219A (ja) * | 1981-09-22 | 1983-03-28 | Sumitomo Chem Co Ltd | パ−キンソン病治療剤 |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US4446138A (en) * | 1982-02-10 | 1984-05-01 | Pack Howard M | Method and composition for reducing weight |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4440740A (en) * | 1982-04-26 | 1984-04-03 | Merck & Co., Inc. | α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption |
| JPS6067420A (ja) * | 1983-09-22 | 1985-04-17 | Sumitomo Chem Co Ltd | 精神運動興奮抑制剤 |
| JPS61100526A (ja) * | 1984-10-22 | 1986-05-19 | Kyowa Hakko Kogyo Co Ltd | 持続性ドパミン経黒剤 |
| NZ220599A (en) * | 1986-06-16 | 1990-10-26 | Merck & Co Inc | Controlled release oral dosage formulation of carbidopa and levodopa |
| SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
| IL110896A0 (en) * | 1994-01-31 | 1994-11-28 | Loral Qualcomm Satellite Serv | Active transmit phases array antenna with amplitude taper |
-
1988
- 1988-07-25 US US07/223,861 patent/US4832957A/en not_active Expired - Lifetime
- 1988-12-02 DE DE8888202760T patent/DE3875705T2/de not_active Expired - Lifetime
- 1988-12-02 EP EP88202760A patent/EP0320051B1/en not_active Expired - Lifetime
- 1988-12-02 AT AT88202760T patent/ATE81970T1/de not_active IP Right Cessation
- 1988-12-02 ES ES88202760T patent/ES2052691T3/es not_active Expired - Lifetime
- 1988-12-02 IL IL88563A patent/IL88563A0/xx unknown
- 1988-12-05 PT PT89157A patent/PT89157B/pt not_active IP Right Cessation
- 1988-12-08 JP JP63309001A patent/JPH0667830B2/ja not_active Expired - Lifetime
- 1988-12-09 CA CA000585578A patent/CA1318602C/en not_active Expired - Lifetime
- 1988-12-09 IE IE367988A patent/IE61547B1/en not_active IP Right Cessation
- 1988-12-09 DK DK685888A patent/DK170515B1/da not_active IP Right Cessation
- 1988-12-09 AU AU26733/88A patent/AU616449B2/en not_active Expired
- 1988-12-10 KR KR1019880016416A patent/KR890009377A/ko not_active Ceased
-
1992
- 1992-11-12 GR GR920402556T patent/GR3006220T3/el unknown
-
1997
- 1997-01-16 HK HK7997A patent/HK7997A/en not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| 高木敬次郎他編「薬物学」（１９８４）南山堂，Ｐ．２２４−２２５ |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008087882A1 (ja) | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | 胃内滞留型レボドパ徐放性製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| US4832957A (en) | 1989-05-23 |
| HK7997A (en) | 1997-01-24 |
| GR3006220T3 (enExample) | 1993-06-21 |
| DK170515B1 (da) | 1995-10-09 |
| IL88563A0 (en) | 1989-07-31 |
| JPH02209A (ja) | 1990-01-05 |
| IE883679L (en) | 1989-06-11 |
| IE61547B1 (en) | 1994-11-16 |
| DE3875705T2 (de) | 1993-05-13 |
| PT89157B (pt) | 1993-06-30 |
| KR890009377A (ko) | 1989-08-01 |
| DK685888D0 (da) | 1988-12-09 |
| CA1318602C (en) | 1993-06-01 |
| EP0320051A1 (en) | 1989-06-14 |
| AU2673388A (en) | 1989-06-15 |
| DK685888A (da) | 1989-07-25 |
| AU616449B2 (en) | 1991-10-31 |
| ATE81970T1 (de) | 1992-11-15 |
| EP0320051B1 (en) | 1992-11-04 |
| ES2052691T3 (es) | 1994-07-16 |
| PT89157A (pt) | 1989-12-29 |
| DE3875705D1 (de) | 1992-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0667830B2 (ja) | カルビドパ／レボドパの制御放出配合剤 | |
| EP0253490B1 (en) | Controlled release combination of carbidopa/levodopa | |
| US4900755A (en) | Controlled release combination of carbidopa/levodopa | |
| US4983400A (en) | Controlled release combination of carbidopa/levodopa | |
| CA2298659C (en) | Fast-acting analgesic | |
| MXPA05002827A (es) | Formulaciones farmaceuticas de modafinil. | |
| US6905707B2 (en) | Controlled release arginine alpha ketoglutarate | |
| KR100894465B1 (ko) | 레보도파의 지속적 효과를 위한 조성물 및 제형 | |
| AU2010258345A1 (en) | Novel pharmaceutical compositions containing pregabalin | |
| US20060159751A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| US5519057A (en) | Ibuprofen-containing medicament | |
| EP1945188A2 (en) | Levodopa compositions | |
| CA2476744A1 (en) | Solid pharmaceutical compositions comprising lumiracoxib | |
| BG61200B2 (bg) | Контролирано отделяща комбинация от саrвidора/lеvоdора | |
| BG61201B2 (bg) | Контролирано отделяща комбинация от саrвidора/lеvоdора | |
| JPH09136833A (ja) | 疲労回復のための組成物 | |
| WO2006025029A2 (en) | Extended release composition of divalproex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070831 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080831 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080831 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090831 Year of fee payment: 15 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090831 Year of fee payment: 15 |